3-tert-Butoxy-propionamide | 90048-42-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-tert-Butoxy-propionamide
• 英文别名: 3-[(2-Methylpropan-2-yl)oxy]propanamide
• CAS: 90048-42-3
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: ZJSNYJSSWTYQOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20030134849A1

  公开（公告）日：2003-07-17

  A compound of formula (I) in which R 1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R 2 is amidated carboxy, R 3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor &agr; (TNF &agr;).

  式(I)的化合物，其中R1是卤素、低碳氧基、可选取代芳基、可选取代芳氧基、可选取代杂环基或可选取代低炔基，R2是酰胺化羧基，R3是氢或酰基，Ar是芳基或杂环基，X是硫代、亚砜基或磺酰基，Y和Z是各自的低碳链基，m和n分别是0到2的整数，以及其盐，用作基质金属蛋白酶（MMP）抑制剂或肿瘤坏死因子α（TNFα）的产生。
• [EN] CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS<br/>[FR] LIGANDS CD33 APPROPRIÉS POUR ÊTRE INCORPORÉS DANS DES SUPPORTS
  申请人：GLYCOMIMETICS INC

  公开号：WO2021222767A1

  公开（公告）日：2021-11-04

  CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand-bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described. The ligands have formula (I) below.

  本文描述了用于合成携带CD33配体的载体的CD33配体，其中所述CD33配体携带的载体与至少一种抗癌剂直接或间接地连接或关联。本文还描述了使用所述CD33配体携带的载体治疗和/或预防疾病、障碍或状况，例如急性髓系白血病（AML）。该配体具有以下式子（I）的公式。
• [EN] THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES DE L'ACIDE THIAZEPINYLHYDROXAMIQUE EN TANT QU'INHIBITEURS DES METALLOPROTEINASES MATRICIELLES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2001060808A1

  公开（公告）日：2001-08-23

  A compound of formula (I) in which R1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R2 is amidated carboxy, R3 is hydrogen or acyl, Ar is aryl or heterocyclic group, X is thia, sulfinyl or sulfonyl, Y and Z are each lower alkylene, m and n are each an integer of 0 to 2, and a salt thereof, useful as inhibitors of matrix metalloproteinases (MMP) or the production of tumor necrosis factor α (TNF α).

  化合物的化学式为（I），其中R1为卤素，较低的烷氧基，可选取代芳基，可选取代芳氧基，可选取代杂环基或可选取代较低的炔基，R2为酰胺化的羧基，R3为氢或酰基，Ar为芳基或杂环基，X为硫代基，亚砜基或磺酰基，Y和Z均为较低的烷基，m和n均为0到2的整数，以及其盐，用作基质金属蛋白酶（MMP）或肿瘤坏死因子α（TNFα）的抑制剂。
• N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：US20160024097A1

  公开（公告）日：2016-01-28

  The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I中的N-(4-(氮杂吲唑-6-基)-苯基)-磺酰胺，其中Ar、n、X、Z、R1、R2和R3在权利要求中指定了它们的含义。式I化合物是有价值的药理活性化合物，可以调节蛋白激酶活性，特别是血清和糖皮质激素调节激酶（SGK）的活性，特别是血清和糖皮质激素调节激酶亚型1（SGK-1，SGK1）的活性，并适用于治疗SGK活性不当的疾病，例如退行性关节疾病或炎症过程，如骨关节炎或风湿病。此外，本发明还涉及制备式I化合物的方法，它们作为药物的用途以及包含它们的制剂。
• Pyridazinone derivatives
  申请人：TEIKOKU HORMONE MFG. CO., LTD.

  公开号：EP0404050A1

  公开（公告）日：1990-12-27

  A pyridazinone compound represented by the general formula wherein Ar is in which R', R2 and R3 may be identical or different, and each represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, a halogen atom, a cyano group or a nitro group, and R' represents a hydrogen atom, a lower alkoxy group, or a lower alkyl group substituted by a lower alkoxy group or a carbamoyl group, and C* is an assymmetric carbon atom, or a salt thereof. This compound is useful for the treatment of diseases of the circulatory system.

  由通式表示的哒嗪酮化合物 其中 Ar 是 其中 R'、R2 和 R3 可以相同或不同，各自代表氢原子、低级烷基、三氟甲基、卤素原子、氰基或硝基，R'代表氢原子、低级烷氧基或被低级烷氧基或氨基甲酰基取代的低级烷基，且 C* 为不对称碳原子、 或其盐。该化合物可用于治疗循环系统疾病。